Sitting, nonambulatory SMA patients (biallelic SMN1 loss, three SMN2 copies, aged 6–<60 months) received a single dose of intrathecal onasemnogene abeparvovec. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.